Response to treatment (N = 34)
| Response . | N (%) . |
|---|---|
| Therapy cycles delivered within trial | |
| Median | 4.5 |
| Range | 1-6 |
| Best response ≥PR | 22 (65) |
| 90% CI, % | 49-76 |
| Best response categories* | |
| VGPR | 5 (15) |
| PR | 17 (50) |
| MR | 3 (9) |
| SD | 4 (12) |
| VGPR + PR + MR | 25 (74) |
| Best response ≥PR per subgroup | |
| Poor-risk cytogenetics (n = 13)† | 10 (77) |
| <5 prior therapies (n = 15) | 10 (67) |
| ≥5 prior therapies (n = 19) | 12 (63) |
| BTZ-LEN double refractory (n = 27) | 19 (70) |
| BTZ-POM double refractory (n = 15) | 9 (60) |
| BTZ-LEN-POM triple refractory (n = 13) | 8 (62) |
| Time to new antimyeloma therapy or death resulting from any cause, w | |
| Median | 16 |
| 95% CI | 13-24 |
| Response . | N (%) . |
|---|---|
| Therapy cycles delivered within trial | |
| Median | 4.5 |
| Range | 1-6 |
| Best response ≥PR | 22 (65) |
| 90% CI, % | 49-76 |
| Best response categories* | |
| VGPR | 5 (15) |
| PR | 17 (50) |
| MR | 3 (9) |
| SD | 4 (12) |
| VGPR + PR + MR | 25 (74) |
| Best response ≥PR per subgroup | |
| Poor-risk cytogenetics (n = 13)† | 10 (77) |
| <5 prior therapies (n = 15) | 10 (67) |
| ≥5 prior therapies (n = 19) | 12 (63) |
| BTZ-LEN double refractory (n = 27) | 19 (70) |
| BTZ-POM double refractory (n = 15) | 9 (60) |
| BTZ-LEN-POM triple refractory (n = 13) | 8 (62) |
| Time to new antimyeloma therapy or death resulting from any cause, w | |
| Median | 16 |
| 95% CI | 13-24 |